Electroencephalography (EEG) Biofeedback Training to Improve Executive Functioning and Memory in Adults With a Dementing Illness (QMFFTD)
|First Received Date ICMJE||July 21, 2010|
|Last Updated Date||July 22, 2010|
|Start Date ICMJE||June 2007|
|Primary Completion Date||June 2008 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||No Changes Posted|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Electroencephalography (EEG) Biofeedback Training to Improve Executive Functioning and Memory in Adults With a Dementing Illness|
|Official Title ICMJE||Pilot Study of EEG and Cerebral Blood Flow Biofeedback Training in Remediating Cognitive and Behavioral Deficits in Adults With a Dementing Illness.|
|Brief Summary||This study measures whether the symptoms of frontotemporal dementia (FTD) can be successfully treated by (a) biofeedback training to increase brain blood flow, (b) biofeedback to increase the frequency of the brain's dominant brainwave rhythm, and (c) rhythmic stimulation to increase the brain's dominant brainwave frequency.|
Objectives and Significance
An additional goal of the study is to contribute to the understanding of how neurofeedback works. For instance, we will take measurements to determine if learning to control the PAF involves awareness of some internal subjective state related to the PAF. Also, the effect of the reward signal on a brainwave called the P300 may show the importance of having the reward tone sounding the majority of the time during neurofeedback sessions. Finally, we will measure whether blood flow changes during EEG biofeedback and whether the EEG is affected by blood flow biofeedback.
We propose several measurements that will contribute to an understanding of the mechanism of action of neurofeedback.
Frontotemporal Dementia and Cerebral Hyperperfusion Single photon emission computed tomography (SPECT) studies have shown cerebral blood flow to be significantly reduced in the frontal and temporal regions in FTD patients (Miller et al., 1997; Read et al., 1995). The anatomical distribution of reduced CBF corresponds to the pattern of neuropsychological deficits (McMurtray et al., 2006).
Not surprisingly, magnetic resonance imaging (MRI) and computed tomography (CT) in FTD patients shows atrophy in the frontal and temporal regions (Mendez et al., 1996; Neary and Snowden, 1996). However, Spilt et al. (2005) hypothesized that neurodegeneration and dementia are largely secondary to pathologies of cerebral blood flow. When compared to elderly controls with optimal cognitive function, patients with DSM-IV dementia did not differ significantly from elderly controls with respect to the number of cerebral infarctions. Demented patients showed significantly more white matter lesions (p=.028) and cerebrospinal fluid (CSF; p=.016), but a reduction in cerebral blood flow had the largest effect size (p<.001). An attempt to build a logistic regression model showed that no significant residual variance could be explained after cerebral blood flow was included in the model.
Another argument for the central role of blood flow in dementia is that Alzheimer's patients with brain damage (regions of MRI signal hyperintensity) have increased oxygen extraction per mL/min. That is, blood supply rather than demand seems to be the problem. Oxygen extraction would be expected to be unaltered if reduced blood flow were secondary to tissue damage (Spilt et al., 2005; Yamaji et al, 1997).
Positron emission tomography (PET) imaging in FTD patients reveals reduced glucose metabolism in the frontal and anterior temporal lobes, but also in the cingulate gyrus, insula, uncus, and subcortical structures (Jeong et al., 2005; Garraux et al., 1999; Ishi et al., 1998). Grimmer et al. (2003) performed a longitudinal study on ten patients diagnosed with FTD. At the initial assessment, FTD patients had reduced metabolic activity compared to controls in frontal cortical areas, the caudate nuclei, and the thalami. On a 1-2 year follow-up, significant progression of the original deficits was observed in the orbitofrontal cortex and the subcortical structures.
Given the substantial evidence linking dementia and FTD in particular to reduced cerebral blood flow, we hypothesize that training FTD patients to increase cerebral blood flow will alleviate FTD symptoms and slow the progress of the disease.
Recent studies have suggested that individuals can learn to increase CBF through biofeedback. Yoo et al. (2006) showed that participants given feedback of fMRI activity of the auditory cortex while listening to music were able to significantly increase the mean blood oxygenation as well as the number of significant voxels. Another study (deCharms et al., 2005) trained participants to change fMRI activity in the rostral anterior cingulate gyrus (RACG), a region implicated in pain perception. Control conditions included sham feedback or feedback from a different brain region. When a noxious thermal stimulus was applied, participants had decreased pain sensation when trained to decrease RACG activity and increased pain sensation when trained to increase RACG activity. In another phase of the study, eight chronic pain patients reported decreased pain after down-training fMRI in the same region.
fMRI costs more than $1000 per session, which places this form of therapy beyond the reach of most patients. However, it is possible to provide CBF neurofeedback for the outermost 1.5 cm of cerebral cortex with a relatively inexpensive device that uses the refractive properties of oxygenated hemogoblin to red and infrared light (Toomim et al., 2004). A light source is attached to the scalp (typically on the forehead) with a headband, 3 cm away from an infrared sensor, which detects the relative absorption by oxygenated blood. This procedure is known as hemoencephalography or HEG. Toomim et al. (2004) showed that ten sessions improved impulsivity scores on the Test Of Variables of Attention (TOVA) in 28 patients of diverse psychopathology. Carmen (2004) provided frontal HEG to 100 migraine patients, and found that 90% of those who completed at least six sessions reported significant improvement in migraine symptoms. In a single case study, Mize (2004) reported that a child with ADHD showed significant improvement on the IVA, which improvement persisting into the 18-month follow-up.
Frontotemporal Dementia and Peak Alpha Frequency
The PAF in health adults has an average of 10-11 Hz. Higher PAF is associated with higher memory performance (Klimesch, 1997), reading ability (Suldo, 2000), vocabulary, and response control (Angelakis et al., 2004a). After a series of cognitive tasks, PAF was reduced in traumatic brain injury patients compared to normal controls, but only weakly or nonsignificantly reduced compared to controls during the task or the baseline conditions. Thus, Angelakis et al. (2004b) argued that PAF is both a trait and a state marker of cognitive preparedness. Passant et al (2005), Chan et al. (2004) and Yenner et al. (1996) all observed a reduction in PAF in FTD patients.
We hypothesize that EEG biofeedback rewarding higher PAF will result in an improvement in symptoms in FTD patients. In EEG biofeedback or neurofeedback, an individual's real-time EEG is presented continuously as a visual or auditory signal, and desired variations are rewarded. A recent double-blind controlled study (Angelakis et al., 2007) showed that neurofeedback rewarding increased PAF improved cognitive processing speed and executive function in normal elderly adults.
The efficacy of neurofeedback as a therapy has been demonstrated for attention deficit hyperactivity disorder (ADHD), epilepsy, anxiety, and addictive disorders. Other disorders such as schizophrenia, depression, learning disabilities (LD), and traumatic brain injury are under investigation as candidates for neurofeedback therapy (Monastra, 2003).
Frontotemporal Dementia and EEG-Driven AVS
Like EEG neurofeedback, EEG-dependent auditory and visual stimulation (AVS), has showed promise for improving cognitive function by modifying the PAF. A substantial body of research has demonstrated that rhythmic AVS can induce EEG rhythms corresponding to the frequency of stimulation (Frederick et al., 2004). Russell (1997) reported on a study in which the continuously varying PAF of LD and ADHD children was used as a signal to produce AVS alternately at 5% above and 5% below the PAF for 30 second intervals, for 20 minute sessions. While the theoretical aim of this study was to improve the flexibility of the PAF (not to change the mean frequency), it showed that treating the PAF can effectively treat cognitive dysfunction. These children showed significant gains in cognitive and behavioral measures that persisted to the 16-month follow-up.
We hypothesize concurrent EEG-Driven photostimulation during PAF enhancement neurofeedback (where rewards are presented as auditory tones, with eyes closed) will increase the rate of learning of PAF enhancement, and have increased therapeutic efficacy compared to PAF neurofeedback alone. In addition to helping induce higher PAF, rhythmic photostimulation has the benefit of increasing CBF by inducing repetitive waves of activation throughout the brain. It may therefore also enhance the effects of the HEG training described above in part I.
Understanding the mechanism of action of neurofeedback could potentially lead to more refined methods of treatment with improved efficacy. We propose three measurements that would contribute to an improved understanding of how neurofeedback works.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 2|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Estimated Enrollment ICMJE||42|
|Completion Date||June 2008|
|Primary Completion Date||June 2008 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
FTD Symptoms reported by self or caregiver Significantly abnormal scores on Delis-Kaplan Executive Function System and Behavior Rating Inventory of Executive Function- Adult Version
|Ages||45 Years to 85 Years (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT01168466|
|Other Study ID Numbers ICMJE||QMFFTD|
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||Not Provided|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Marvin H. Berman PhD, Principal Investigator, Quietmind Founcation|
|Study Sponsor ICMJE||Quietmind Foundation|
|Collaborators ICMJE||Not Provided|
|PRS Account||Quietmind Foundation|
|Verification Date||July 2010|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP